Radiotherapy for Ocular melanomas

The research group is part of the Leiden Ocular Tumor Center (LOTC). Leiden UMC treats the large majority of ocular melanomas in The Netherlands and of that most patients are treated with brachytherapy, photons and protons. The research activity aims at improving outcomes and to establish the best proton eye treatment in the world by 2024. Research is on patient outcomes and technique development.

The clinical outcome of uveal melanoma with proton treatment is subject of various research projects. The overall aim is to develop the best treatment with protons in the world. For this we need to investigate what parts of the eye can withstand what treatment (layover 2), develop tools to improve accuracy (layover 1) measure the quality of life of the patients (Proqem project layover 1) improve decision making of the patients before treatment and develop techniques to translate this into clinical practice (layover 1) and monitor and stepwise improve the outcome of smaller melanomas treated with brachytherapy (layover 3).

Team

  • Prof. dr. C. Rasch (group leader)
  • Prof. dr. C. Creutzberg (Brachytherapy)
  • Dr. N. Horeweg (Epidemilogist)
  • T. Alderliesten (AI)
  • Dr. P. Bakker
  • Drs. M. Hol
  • Drs. L. Pos
  • Drs. A. Shirzada
  • Drs. B Kinaci
  • Dr. K. Hassan

External collaborators

  • Prof. dr. G. Luyten
  • Drs. M. Marinkovic
  • Dr. Y. Klaver
  • Dr. JW Beenakker
  • Dr. A Pieterse
  • Dr. K. Vu
  • Dr. J. Bleeker